Creative Planning’s Matinas BioPharma MTNB Stock Holding History

Creative Planning’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,065	Closed	-$187K	–	2046
2018 Q3	$187K	Hold	4,065	–	–	﹤0.01%	1693
2018 Q2	$88K	Buy	+4,065	New	+$117K	﹤0.01%	1790
2017 Q4	–	Sell	-745	Closed	-$49K	–	1972
2017 Q3	$49K	Hold	745	–	–	﹤0.01%	1778
2017 Q2	$63K	Hold	745	–	–	﹤0.01%	2331
2017 Q1	$103K	Buy	+745	New	+$121K	﹤0.01%	1936

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Planning's MTNB Position: Q4 2018 in Review

Creative Planning sold out of Matinas BioPharma (MTNB) in Q4 2018, closing a stake of 4,065 shares — an estimated $187K sold.

Creative Planning first reported a position in MTNB in Q1 2017 and held it in 5 quarters. The position peaked at $187K in Q3 2018. 35 funds tracked by Wall St. Rank hold MTNB as of Q4 2018.

Creative Planning reported no remaining Matinas BioPharma position as of Q4 2018 after selling out during the quarter.
Creative Planning sold 4,065 Matinas BioPharma shares in Q4 2018, an estimated $187K.
Creative Planning first reported a position in Matinas BioPharma in Q1 2017 and held it in 5 quarters.
Creative Planning's Matinas BioPharma position peaked at $187K in Q3 2018.
35 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2018.

Based on Creative Planning's 13F filing for Q4 2018, filed 1 Feb 2019.